What question did this study set out to answer?

The aim is to compare the efficacy of nucleoside monotherapy versus combination therapy in HIV-infected adults with specific CD4 counts.

October 10, 1996Open Access

A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter

Puntos clave

The aim is to compare the efficacy of nucleoside monotherapy versus combination therapy in HIV-infected adults with specific CD4 counts.
Compared treatments: zidovudine plus didanosine, zidovudine plus zalcitabine, and didanosine alone.
Population: HIV-infected adults with CD4 counts from 200 to 500 cells/mm³.
Analyzed survival rates and progression of HIV disease.
Combination therapy is superior to zidovudine alone in slowing HIV progression.
Increased survival rates observed in patients receiving combination therapy compared to monotherapy.

Resumen

Treatment with zidovudine plus didanosine, zidovudine plus zalcitabine, or didanosine alone slows the progression of HIV disease and is superior to treatment with zidovudine alone. Antiretroviral therapy can improve survival in patients with 200 to 500 CD4 cells per cubic millimeter.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Hammer et al. (Thu,) studied this question.

synapsesocial.com/papers/69d6cf34f174babf6cab39bc https://doi.org/https://doi.org/10.1056/nejm199610103351501

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Me gusta

Guardar

Ver artículo completo